Olanzapine as an antiemetic in intractable nausea and anorexia in patients with advanced hepatocellular carcinoma: Three case series

Kanzo/Acta Hepatologica Japonica

Volumn 50, Issue 3, 2009, Pages 153-158

  Kitada, Takuya ^a   Narimatsu, Takashi ^a   Yamaguchi, Seiko ^a  

^a Fuchu Hospital   (Japan)

Author keywords

Anorexia; Hepatocellular carcinoma; Olanzapine; Refractory nausea

Indexed keywords

ANTIEMETIC AGENT; OLANZAPINE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CASE REPORT; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; MALE; NAUSEA;

EID: 66149163244     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.50.153     Document Type: Article

References (20)

1. Seeman P, Van Tol H. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6: 602-660
2. Bymaster F, Calligaro D, Falcone J, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsycopharmacology 1996; 14: 87-96
3. Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group Study. Cancer Invest 2004; 22 (3): 383-388
4. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group Study. Support Care Cancer 2005; 13 (7): 529-534
5. Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med 2003; 6: 251-255
6. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003; 25 (6): 578-582
7. Mannix KA. Palliation of nausea and vomiting. In: Oxford Textbook of Palliative Medicine, Edited by D Doyle, GWC Hanks, N MacDonald, 3rd ed., Oxford University Press, New York, 2004, p459-468
8. Twycross R, Black I. Nausea and vomiting in advanced cancer. Eur J Palliat Care 1998; 5: 39-45
9. Stephenson J, Davis A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer 2006; 14: 348-353
10. Lin MH, Wu PY, Tsai ST, et al. Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliat Med 2004; 18 (2): 93-99
11. Sun V, Ferrell B, Juarez G, et al. Symptom concerns and quality of life in hepatobiliary cancers. Oncol Nurs Forum 2008; 35 (3): E45-52
12. Chen CY, Lu CL, Chang FY, et al. Delayed liquid gastric emptying in patients with hepatocellular carcinoma. Am J Gastroenterol 2000; 95 (11): 3230-3237
13. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004; 37 (1): 1-11
14. Ozcanli T, Erdogan A, Ozdemir S, et al. Severe liver enzyme elevations after three years of olanzapine treatment a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1163-1166
15. Morita T, Tei Y, Shishido H, et al. Olanzapine-induced delirium in a terminally ill cancer patient. J Pain Symptom Manage 2004; 28: 102-103
16. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156 (11): 1686-1696
17. Gupta S, Droney T, Al-Samarrai S, et al. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999; 19 (3): 273-274
18. Bissada H, Tasca GA, Barber AM et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165 (10): 1281-1288
19. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; e1-e7